In addition, rosiglitazone reduces the expression of the leptin receptors, antagonizes the leptin signal, and inhibits the MAPK/STAT3/Akt pathway [126], suggesting that PPARγ agonists may have a potential role in the treatment of breast cancer patients. Here, LEP is linked to breast cancer.